Could a simple injection before and after surgery keep colorectal cancer at bay?

NCT ID NCT05677113

Ongoing Disease control Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a drug called QBECO, given as a self-injection before and after liver surgery, can lower the chance of colorectal cancer coming back or spreading. About 115 adults with colorectal cancer that has spread to the liver will take part. They will inject the drug for at least 11 days before surgery and 41 days after, then be followed for up to 5 years. The goal is to see if this approach improves cancer control compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER LIVER METASTASES

Contacts and locations

Locations

Hamilton Health Science Centre

Hamilton, Ontario, Canada
London Health Science Centre

London, Ontario, Canada
Sunnybrook Health Science Centre

Toronto, Ontario, L4H1Z9, Canada
The Ottawa Hospital

Ottawa, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.